Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2005-04-19
2008-11-25
Desai, Rita J (Department: 1625)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C546S080000
Reexamination Certificate
active
07456193
ABSTRACT:
The present invention relates to pyridoindolone derivatives substituted in the 3-position by a heterocyclic group of general formula (I):in which:R1represents a hydrogen atom or a (C1-C4)alkyl group;R2represents a hydrogen atom or a (C1-C4)alkyl group;R3represents a thienyl mono- or polysubstituted by a methyl group; or a monocyclic or bicyclic heterocyclic radical chosen from: a pyridyl, an N-oxidopyridinio, a pyrazolyl, an (N-phenyl)pyrazolyl, an (N-halophenyl)pyrazolyl, a furyl, an indolyl, an (N-benzyl)indolyl, an (N-halobenzyl)indolyl, a benzothienyl or a benzofuryl, the said radicals being unsubstituted or substituted one or more times by a halogen atom or a methyl or methoxy group;R4and R5are identical or different and each independently represent a hydrogen or halogen atom or a hydroxyl, hydroxymethyl, (C1-C4)alkyl, trifluoromethyl, C1-C4)alkoxy, (C1-C4)alkoxycarbonyl or cyano group.Preparation process and application in therapeutics.
REFERENCES:
patent: 4263304 (1981-04-01), Ishizumi et al.
patent: 4835160 (1989-05-01), Bisagni et al.
patent: 5880126 (1999-03-01), Skuballa et al.
patent: 6503888 (2003-01-01), Kaplitt et al.
patent: 6967203 (2005-11-01), Bourrie et al.
patent: 2002/0156016 (2002-10-01), Minuk
patent: 2004/0122027 (2004-06-01), Bourrie et al.
patent: 2004/0122036 (2004-06-01), Bourrie et al.
patent: 2 003 999 (1969-11-01), None
patent: 2 765 581 (1999-01-01), None
patent: 2 765 582 (1999-01-01), None
patent: 833971 (1981-05-01), None
patent: WO 99/51597 (1999-10-01), None
patent: WO 01/09129 (2001-02-01), None
patent: WO 02/087574 (2002-11-01), None
patent: WO 02/087575 (2002-11-01), None
patent: WO 2004/037817 (2004-05-01), None
patent: WO 2005/108398 (2005-11-01), None
patent: WO2007045758 (2007-04-01), None
Sausville et al. Human tumor Xenograft . . . 2006.
U.S. Appl. No. 11/109,068, Bourrie et al.
Furihata, C., et al., In Vivo Short-Term Assays For Tumor Initiation ANd Promotion In The Grandular Stomach Of Fischer Rats, Mutation Research, (1995), vol. 339, No. 1, pp. 15-35.
Furihata, C., et al., Unscheduled DNA Synthesis In Rat Stomach-Short-Term Assay Of Potential Stomach Carcinogens, Banbury Report, (1982), vol. 13, pp. 123-135.
Golovko, T., et al., A New Approach To The Synthesis Of Functionally-Substituted Pyrido 2, 3-D Indoles, Mendeleev Communications, (1995), vol. 6, pp. 226-227.
Molina, P., et al., Annulation Of Pyridine To Indole By A Tandem Aza-Wittig/Electrocyclization Strategy: Synthesis Of Pyrido 2, 3-B Indoles, Synthesis, (1989), vol. 11, pp. 878-880.
Froissant et al., Derwent Patent Abstract No. 199909 (2003) (abstract of FR 2 765 581).
Goldman M.D., et al., Cecil, Textbook of Medicine, 21st edition, vol. 1, published 2000 by W.B. Saunders Co. (PA), pp. 1060-1074.
Abstract No. 1982-25808e (XP-002184731, DW 198213) (1982).
Derwent Patent Abstract No. 196800 (2003).
Maribout Benoit et al, Derwent Patent Abstract No. 199909 (2003), (Abstract of FR 2 765 582).
Goodman & Gilman, Section X. Chemotherapy of Neoplastic Diseases, Goodman & Gilman's The Pharmacological Basis of Therapeutics, 9th Ed., (1996) pp. 1225-1232 and pp. 1269-1271.
Nicholson-Guthrie et al, Urine GABA Levels in Ovarian Cancer Patients: elevated GABA in malignancy, Cancer Letters, vol. 162, Issue 1, (2001), pp. 27-30.
U.S. Appl. No. 11/582,769, filed Oct. 18, 2006, Bourrie.
Bourrie Bernard
Casellas Pierre
Derocq Jean-Marie
Jegham Samir
Muneaux Yvette
Bender Kelly L.
Desai Rita J
Sanofi-Aventis
LandOfFree
Pyridoindolone derivatives substituted in the 3-position by... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Pyridoindolone derivatives substituted in the 3-position by..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Pyridoindolone derivatives substituted in the 3-position by... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4039037